VYNE Therapeutics Announces $50 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules

January, 26 2021

BRIDGEWATER, N.J., Jan. 26, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”),  today announced that it has entered into definitive agreements with institutional and accredited investors for the sale of an aggregate of 21,097,046 shares of its common stock at a purchase price of $2.37 per share in a registered direct offering priced at-the-market under Nasdaq Rules. The offering is expected to close on or about January 28, 2021, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds of the…

Read More

VYNE Therapeutics Announces Contract Execution for AMZEEQ® (minocycline) and ZILXI® (minocycline) with Major Pharmacy Benefit Management (PBM) Company

January, 21 2021

BRIDGEWATER, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced the execution of a contract with a major PBM for its novel AMZEEQ® (minocycline) topical foam, 4% and ZILXI® (minocycline) topical foam, 1.5%. AMZEEQ, the first topical minocycline to be approved by the U.S. Food and Drug Administration (“FDA”) for any condition, is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older. ZILXI is indicated for the treatment of inflammatory lesions of rosacea in adults and…

Read More